| The role of insulin-like growth factor binding protein-3 in the breast cancer cell response to DNA-damaging agents MZ Lin, KA Marzec, JL Martin, RC Baxter Oncogene 33 (1), 85-96, 2014 | 80 | 2014 |
| Targeting insulin-like growth factor binding protein-3 signaling in triple-negative breast cancer KA Marzec, RC Baxter, JL Martin BioMed research international 2015, 2015 | 79 | 2015 |
| The oncogenic functions of MASTL kinase K Marzec, A Burgess Frontiers in cell and developmental biology 6, 162, 2018 | 27 | 2018 |
| Involvement of p53 in insulin-like growth factor binding protein-3 regulation in the breast cancer cell response to DNA damage KA Marzec, MZ Lin, JL Martin, RC Baxter Oncotarget 6 (29), 26583, 2015 | 24 | 2015 |
| A non-genetic, cell cycle-dependent mechanism of platinum resistance in lung adenocarcinoma A Gonzalez Rajal, KA Marzec, RA McCloy, M Nobis, V Chin, JF Hastings, ... Elife 10, e65234, 2021 | 14 | 2021 |
| YB-1 knockdown inhibits the proliferation of mesothelioma cells through multiple mechanisms TG Johnson, K Schelch, K Lai, KA Marzec, M Kennerson, M Grusch, ... Cancers 12 (8), 2285, 2020 | 11 | 2020 |
| The BARD1 BRCT domain contributes to p53 binding, cytoplasmic and mitochondrial localization, and apoptotic function V Tembe, E Martino-Echarri, KA Marzec, MTS Mok, KM Brodie, K Mills, ... Cellular signalling 27 (9), 1763-1771, 2015 | 11 | 2015 |
| BARD1 splice variants display mislocalization in breast cancer cells and can alter the apoptotic response to cisplatin KA Marzec, E Martino-Echarri, I Irminger-Finger, BR Henderson Cancer letters 381 (1), 149-155, 2016 | 7 | 2016 |
| SILAC kinase screen identifies potential MASTL substrates KA Marzec, S Rogers, R McCloy, BL Parker, DE James, DN Watkins, ... Scientific Reports 12 (1), 10568, 2022 | 2 | 2022 |
| SnapShot: S-phase entry and exit A Burgess, J Vuong, KA Marzec, UN de Lichtenberg, SI O’Donoghue, ... Cell 179 (3), 802-802. e1, 2019 | 2 | 2019 |
| C. elegans model of riboflavin transporter deficiency (RTD) disorder reveals deficits in synaptic transmission and movement RK Narayanan, G Perez-Siles, KA Marzec, A Boyling, B Neumann, ... Genes & Diseases 11 (4), 101071, 2024 | | 2024 |
| In Cellulo Kinase Screen Identifies Potential MASTL Substrates KA Marzec, S Rogers, R McCloy, BL Parker, DE James, DN Watkins, ... | | 2022 |
| Resistance to platinum chemotherapy in lung adenocarcinoma is driven by a non-genetic, cell-cycle dependent mechanism A Gonzalez-Rajal, R McCloy, M Nobis, KA Marzec, V Chin, JF Hastings, ... bioRxiv, 2020.11. 26.400499, 2020 | | 2020 |
| THE ROLE OF SPECIFIC BARD1 SPLICE VARIANT ISOFORMS IN BREAST CANCER CELL RESISTANCE TO DNA DAMAGING AGENTS KA Marzec, E Martino-Echarri, Y Lei, A DeFazio, I Irminger-Finger, ... ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 10, 37-37, 2014 | | 2014 |
| The role of endogenous IGFBP-3 in breast cancer cell responsiveness to DNA damaging therapy KA Marzec University of Sydney, 2013 | | 2013 |
| Insulin-like growth factor binding protein-3 is a key component of the breast cancer cell response to DNA-damaging therapy RC Baxter, MZ Lin, KA Marzec, JL Martin CANCER RESEARCH 72, 2012 | | 2012 |
| Abstract P5-07-05: Insulin-like growth factor binding protein-3 is a key component of the breast cancer cell response to DNA-damaging therapy RC Baxter, MZ Lin, KA Marzec, JL Martin Cancer Research 72 (24_Supplement), P5-07-05-P5-07-05, 2012 | | 2012 |
| OR04-4 Endogenous insulin-like growth factor binding protein 3 (IGFBP-3) contributes to DNA damage-induced apoptosis in breast cancer cells KA Marzec, JL Martin, RC Baxter Growth Hormone & IGF Research, S10-S11, 2012 | | 2012 |
Robert C. BaxterUniversity of SydneyVerified email at sydney.edu.au
